Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study

Langer, Thorsten; Clemens, Eva; Broer, Linda; Maier, Lara; Uitterlinden, André G.; Vries, Andrica C H de; Grotel, Martine van; Pluijm, Saskia F. M.; Binder, Harald; Mayer, Benjamin; Knesebeck, Annika von dem; Byrne, Julianne; Broeder, Eline van Dulmen‐den; Crocco, Marco; Grabow, Desiree; Kaatsch, Peter; Kaiser, Melanie; Spix, Claudia; Kenborg, Line; Winther, Jeanette Falck; Rechnitzer, Catherine; Hasle, Henrik; Kepák, Tomáš; Kooi, Anne-Lotte F. van der; Kremer, Leontien C. M.; Kruseová, Jarmila; Bielack, Stefan; Sorg, Benjamin; Hecker‐Nolting, Stefanie; Kuehni, Claudia E.; Ansari, Marc; Kompis, Martin; Pal, Heleen van der; Parfitt, Ross; Deuster, Dirk; Matulat, Peter; Tillmanns, Amélie; Tissing, Wim J. E.; Beck, J. D.; Elsner, Susanne; Zehnhoff‐Dinnesen, Antoinette am; Heuvel‐Eibrink, Marry M. van den; Zolk, Oliver

doi:10.1016/j.ejca.2020.07.019

Cited by 29 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further study reported a significant association between patients carried SLCO1B1 T521C and myopathy induced by statins, including simvastatin, rosuvastatin and ceruvastatin ( Xiang et al, 2018 ; Carr et al, 2019 ; Turner et al, 2020 ). It has also been reported that SLC6A3 rs28363170 is associated with haloperidol-related ADR ( Zastrozhin et al, 2017 ), SLC22A2 rs316019 is associated with cisplatin-induced ototoxicity in cancer patients ( Langer et al, 2020 ), and S allele of SLC6A4 is involved in serotonin inhibitors-induced mania and gastrointestinal ADR ( Zhu et al, 2017 ).…”

Section: Genetic Factors Of Severe Adverse Drug Reactionsmentioning

confidence: 99%

An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

et al. 2022

View full text Add to dashboard Cite

Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT/NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.

show abstract

Section: Genetic Factors Of Severe Adverse Drug Reactionsmentioning

confidence: 99%

An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Specific genomic mutations may predispose individuals to cisplatin-induced hearing loss, including gene variants for DNA adduct repair enzymes like ERCC2 and XPC ( Caronia et al, 2009 ; Turan et al, 2019 ); antioxidant enzymes; and drug efflux or membrane pumps ACYP2, ABCC3, COMT, and TPMT ( Ross et al, 2009 ; Xu et al, 2015 ). However, the predictive value in identifying these genomic variants in predisposing individuals for cisplatin-induced ototoxicity is currently poor ( Langer et al, 2020 ; Tserga et al, 2019 ). Enhanced cisplatin-induced hearing loss also occurs when co-administered with ototoxic therapeutics, including aminoglycosides, loop diuretics, and cranial radiation ( Clemens et al, 2016 ; McAlpine & Johnstone, 1990 ; Miller et al, 2009 ; Paulino et al, 2010 ).…”

Section: Factors Enhancing the Risk Of Hearing Lossmentioning

confidence: 99%

Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity

Steyger

2021

Am J Audiol

View full text Add to dashboard Cite

Purpose This review article summarizes our current understanding of the mechanisms underlying acquired hearing loss from hospital-prescribed medications that affects as many as 1 million people each year in Western Europe and North America. Yet, there are currently no federally approved drugs to prevent or treat the debilitating and permanent hearing loss caused by the life-saving platinum-based anticancer drugs or the bactericidal aminoglycoside antibiotics. Hearing loss has long-term impacts on quality-of-life measures, especially in young children and older adults. This review article also highlights some of the current knowledge gaps regarding iatrogenic causes of hearing loss. Conclusion Further research is urgently needed to further refine clinical practice and better ameliorate iatrogenic drug-induced hearing loss.

show abstract

“…The genetic make-up of an individual may influence this largely irreversible toxicity. 24 Administration of the drug over a longer period of time in order to lower peak-levels may be beneficial.…”

Section: Chemotherapy: Why When and Howmentioning

confidence: 99%

Bone sarcoma: Success through interdisciplinary collaboration

Hecker‐Nolting

Ferreira

Bielack

2021

Journal of Children's Orthopaedics

Self Cite

View full text Add to dashboard Cite

Purpose Osteosarcoma and Ewing sarcoma are the most frequent malignant bone tumours of childhood and adolescence. This review summarizes the oncologist’s view of these diseases and their treatment. Methods A non-systematic literature review was performed, the personal impressions and experience of the authors is described. Results Local therapy and chemotherapy, each on their own, will not cure patients with malignant bone sarcomas. Together, they present a highly efficacious combination. While the most effective drugs were defined decades ago, progress since then has been limited. It is hoped that substances shown to be active in relapsed disease will be forwarded into even more efficacious frontline treatments. Good palliative therapy is necessary when cure is no longer an option. Conclusion Close interdisciplinary collaboration is the key to successful treatment of bone sarcomas in paediatric patients.

show abstract

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study

Cited by 29 publications

References 43 publications

An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity

Bone sarcoma: Success through interdisciplinary collaboration

Contact Info

Product

Resources

About